Continuous Theta Burst Stimulation as Potential Biomarker of Levodopa-induced Dyskinesias in Parkinson's Disease

Institute of Hospitalization and Scientific Care (IRCCS)

Status: Enrolling

Conditions: Parkinson Disease

Treatments: Device: Continuous theta burst stimulation

Study type: Interventional

Funder types: Other

Identifiers

NCT05795088

3884 (Other Identifier)

Details and patient eligibility

About

The primary endpoint of the study is to identify a neurophysiological biomarker (absence of synaptic depotentiation at primary motor cortex , measured as change in the amplitude of motor evoked potentials recorded at the dorsal first interosseus muscle after administration of neurophysiological cTBS depotentiation protocol) as predictor of the development of Levodopa-induced dyskinesia in patients with Parkinson's disease.

Enrollment: 60 estimated patients

Sex: All

Ages: 30 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with diagnosis of idiopathic Parkinson's disease according to Movement Disorder Society (MDS) criteria;
• age between 30 and 80 years;
• ongoing therapy with levodopa;
• fulfillment of requirements for the application of transcranial magnetic stimulation (TMS), assessed by completion of the TMS screening questionnaire.

Exclusion criteria

• patients unable to give informed consent;
• cognitive impairment (MMSE ≤ 24);
• history of epilepsy;
• pregnant women.

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

60 participants in 1 patient group

Patients with parkinson's disease

Experimental group

Treatment:

Device: Continuous theta burst stimulation